CTLA4 and non-small cell lung carcinoma: Anti-PD-(L)1 ± anti-CTLA-4 antibodies are now routinely used to treat patients with metastatic cancers, including melanoma [12, 13], renal cancer [14, 15], and non-small cell lung cancer (NSCLC) [16, 17] in expectation of improving overall survival.